Peregrine Pharma & AstraZeneca expand ongoing immuno─oncology pact to include phase II lung cancer combo study

… squamous or non-squamous non-small cell lung cancer (NSCLC). The randomized phase II … combination drug in the same lung cancer population. This phase II study …